Serum procalcitonin in pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 2, 2011, Pages 251-256

  Rasmussen, T A ^a   Sogaard O S ^a   Camara, C ^b   Andersen, P L ^a   Wejse, C ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

Author keywords

C reactive protein; Procalcitonin; Prognosis; Tuberculosis

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GUINEA-BISSAU; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIETARY SUPPLEMENTS; FEMALE; GUINEA-BISSAU; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTPATIENTS; PROTEIN PRECURSORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; UP-REGULATION; VITAMIN D;

EID: 78651458669     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. World Health Organization. Global tuberculosis control: surveillance, planning, fi nancing. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
2. Keeler E, Perkins M D, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 2006; 444 (Suppl 1): S49-S57.
3. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-518.
4. Becker K L, Snider R, Nylen E S. Procalcitonin assay in systemic infl ammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36: 941-952.
5. Brunkhorst F M, Wegscheider K, Forycki Z F, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000; 26 (Suppl 2): S148-S152.
6. Kristoffersen K B, Sogaard O S, Wejse C, et al. Antibiotic treatment interruption of uspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission-a randomized trial. Clin Microbiol Infect 2009;15: 481-487.
7. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, singleblinded intervention trial. Lancet 2004; 363: 600-607.
8. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059-1066.
9. Wejse C, Gomes V F, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009;179: 843-850.
10. Harries A D, Maher D, Graham S. TB/HIV: a clinical manual. 2nd ed. WHO/HTM/TB/2004.329. Geneva, Switzerland: WHO,2004.
11. Wejse C, Gustafson P, Nielsen J, et al. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis 2008; 40: 111-120.
12. Raaby L, Bendix-Struve M, Nielsen J, Wejse C. Inter-observer variation of the Bandim TB-score. Scand J Infect Dis 2009; 41: 220-223.
13. Olesen R, Wejse C, Velez D R, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun 2007; 8: 456-467.
14. Wejse C, Olesen R, Rabna P, et al. Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls. Am J Clin Nutr 2007; 86: 1376-1383.
15. Cakir E, Deniz O, Ozcan O, et al. Pleural fl uid and serum procalcitonin as diagnostic tools in tuberculous pleurisy. Clin Biochem 2005; 38: 234-238. (Pubitemid 40222322)
16. Lawn S D, Obeng J, Acheampong J W, Griffin G E. Serum procalcitoninconcentrations in patients with pulmonary tuberculosis. Trans R Soc Trop Med Hyg 1998; 92: 540-541.
17. Zarka V, Valat C, Lemarie E, et al. [Serum procalcitonin and respiratory tract infections]. Rev Pneumol Clin 1999; 55: 365-369. [French]
18. Baylan O, Balkan A, Inal A, et al. The predictive value of serum procalcitonin levels in adult patients with active pulmonary tuberculosis. Jpn J Infect Dis 2006; 59: 164-167.
19. Kandemir O, Uluba B, Polat G, Sezer C, Camdeviren H, Kaya A. Elevation of procalcitonin level in patients with pulmonary tuberculosis and in medical staff with close patient contact. Arch Med Res 2003; 34: 311-314.
20. Naderi M, Hashemi M, Kouhpayeh H, Ahmadi R. The status of serum procalcitonin in pulmonary tuberculosis and nontuberculosis pulmonary disease. J Pak Med Assoc 2009; 59:647-648.
21. Porcel J M, Vives M, Cao G, et al. Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J 2009; 34: 1383-1389.
22. Polzin A, Pletz M, Erbes R, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003; 21: 939-943.
23. Prat C, Dominguez J, Andreo F, et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 2006; 52: 169-177.
24. Kang Y A, Kwon S Y, Yoon H I, Lee J H, Lee C T. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med 2009; 24: 337-342.
25. Nyamande K, Lalloo U G. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 2006; 10: 510-515.
26. Schleicher G K, Herbert V, Brink A, et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 2005; 25: 688-692.
27. Siddiqi K, Lambert M L, Walley J. Clinical diagnosis of smearnegative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 2003; 3: 288-296.
28. Schuetz P, Christ-Crain M, Huber A R, Muller B. Long-term stability of procalcitonin in frozen samples and comparison of Kryptor and VIDAS automated immunoassays. Clin Biochem 2010; 43: 341-344.